Genfit (NASDAQ:GNFT – Get Rating) and Candel Therapeutics (NASDAQ:CADL – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Risk and Volatility

Genfit has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500.

Valuation and Earnings

This table compares Genfit and Candel Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Genfit and Candel Therapeutics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

4.2% of Genfit shares are held by institutional investors. Comparatively, 22.0% of Candel Therapeutics shares are held by institutional investors. 44.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Genfit and Candel Therapeutics, as provided by MarketBeat.com.

Genfit presently has a consensus target price of $9.00, indicating a potential upside of 152.10%. Candel Therapeutics has a consensus target price of $10.33, indicating a potential upside of 526.26%. Given Candel Therapeutics' higher possible upside, analysts plainly believe Candel Therapeutics is more favorable than Genfit.

About Genfit

(Get Rating)

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

About Candel Therapeutics

(Get Rating)

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.